Promising Schizophrenia Drug, Cobenfy, Will Face Access Challenges
Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September.
All posts by Joshua P. Cohen
Read More »
